Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression

Rodrigo B. Mansur 1,2,*†, Francheska Delgado-Peraza 3,4‡, Mehala Subramaniapillai 1, Yena Lee 1,4*, Michelle Iacobucci 1, Nelson Rodrigues 1, Joshua D. Rosenblat 1,2, Elisa Brietzke 1,5, Victoria E. Cosgrove 6, Nicole E. Kramer 6, Trisha Suppes 6, Charles L. Raison 7,8, Sahil Chawla 3, Carlos Nogueras-Ortiz 3‡, Roger S. McIntyre 1,2,4,‡ and Dimitrios Kapogiannis 3,‡

1 Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON M5T 2S8, Canada; m.subram@mail.utoronto.ca (M.S.); yenalee.lee@mail.utoronto.ca (Y.L.); mich.iacobucci@gmail.com (M.I.); nelson.rodrigues@crcte.com (N.R.); Joshua.Rosenblat@uhn.ca (J.D.R.); elisa.brietzke@queensu.ca (E.B.); Roger.McIntyre@uhn.ca (R.S.M.)

2 Department of Psychiatry, University of Toronto, Toronto, ON M5T 2S8, Canada

3 Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health (NIA/NIH), Baltimore, MD 20892, USA; francheska.delgado-peraza@nih.gov (F.D.-P.); sahil.chawla@nih.gov (S.C.); carlos.nogueras-ortiz@nih.gov (C.N.-O.); kapogiannisd@mail.nih.gov (D.K.)

4 Institute of Medical Science, University of Toronto, Toronto, ON M5G 1A8, Canada

5 Kingston General Hospital, Providence Care Hospital, Department of Psychiatry, Queen’s University School of Medicine, Kingston, ON K7L 4X3, Canada

6 Department of Psychiatry & Behavioral Sciences, Stanford University, School of Medicine, Palo Alto, CA 94304, USA; veileen@stanford.edu (V.E.C.); nklange@stanford.edu (N.E.K.); tsuppes@stanford.edu (T.S.)

7 School of Human Ecology, University of Wisconsin-Madison, Madison, WI 53706, USA; raison@wisc.edu

8 Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53722, USA

* Correspondence: rodrigo.mansur@uhn.ca; Tel.: +1416-0358-00; Fax: +1416-0353-68
† These authors share first authorship.
‡ These authors share senior authorship.

Received: 6 March 2020; Accepted: 30 March 2020; Published: 6 April 2020

Abstract: Accumulating evidence suggests that neuroinflammation is involved in bipolar disorder (BD) pathogenesis. The tumor necrosis factor-alpha (TNF-α) antagonist infliximab was recently reported to improve depressive symptoms in a subpopulation of individuals with BD and history of childhood maltreatment. To explore the mechanistic mediators of infliximab’s effects, we investigated its engagement with biomarkers of cellular response to inflammation derived from plasma extracellular vesicles enriched for neuronal origin (NEVs). We hypothesized that infliximab, compared to placebo, would decrease TNF-α receptors (TNFRs) and nuclear factor-kappa B (NF-κB) pathway signaling biomarkers, and that history of childhood abuse would moderate infliximab’s effects. We immunocaptured NEVs from plasma samples collected at baseline and at weeks 2, 6, and 12 (endpoint) from 55 participants of this clinical trial and measured NEV biomarkers using immunoassays. A subset of participants (n = 27) also underwent whole-brain magnetic resonance imaging at baseline and endpoint. Childhood physical abuse moderated treatment by time interactions for TNFR1 (χ² = 9.275, p = 0.026), NF-κB (χ² = 13.825, p = 0.003), and inhibitor of NF-κB (IκBα)α (χ² = 7.990, p = 0.046), indicating that higher levels of physical abuse were associated with larger biomarker decreases over time. Moreover, the antidepressant response to infliximab was moderated by TNFRI (χ² = 7.997, p = 0.046). In infliximab-treated participants, reductions in TNFR1 levels were
Cells 2020, 9, 895 2 of 17

associated with improvement of depressive symptoms, an effect not detected in the placebo group. Conversely, reductions in TNFR1 levels were associated with increased global cortical thickness in infliximab- (r = −0.581, p = 0.029), but not placebo-treated, patients (r = 0.196, p = 0.501). In conclusion, we report that NEVs revealed that infliximab engaged the TNFR/NF-κB neuro-inflammatory pathway in individuals with BD, in a childhood trauma-dependent manner, which was associated with clinical response and brain structural changes.

**Keywords:** bipolar disorder; inflammation; cytokines; childhood trauma; depression

1. Introduction

Replicated evidence indicates that inflammation is a relevant pathophysiological mechanism for a subset of individuals with bipolar disorder (BD). Multiple meta-analyses have documented alterations in peripheral markers of inflammation, such as acute phase proteins (e.g., C-reactive protein [CRP]) and inflammatory cytokines (e.g., tumor necrosis factor-α [TNF-α], interleukin-6 [IL6]) [1,2]. Direct evidence of neuroinflammation has been scarcer, but has supported the hypothesis of inflammatory dysregulation [3–5]. In addition, inflammatory mediators have been consistently associated with neurostructural abnormalities in individuals with BD [6–10]. As a result, anti-inflammatory agents have been recently tested as therapies for mood disorders, including bipolar depression [11–13]. Results have been mixed. For example, whereas anti-cytokine treatments have shown antidepressant activity in chronic inflammatory conditions [13], two recent clinical trials failed to demonstrate this effect in the intent-to-treat cohorts with treatment-resistant major depressive disorder and BD [14,15].

Nonetheless, both studies identified subpopulations, in secondary analyses, who were more likely to respond to the TNF-α antagonist infliximab, based on biochemical (e.g., elevated plasma CRP) or phenotypic criteria (e.g., exposure to early childhood adversity) [14,15]. It remains unclear, however, if these responders represent actual “inflammatory biotypes”, within or across mood disorders, which may be more responsive to anti-inflammatory interventions. Supporting this idea, a follow-up analysis of the study of Raison et al. [14], which identified elevated CRP at baseline as a predictor of favorable response to infliximab, documented that changes in the expression of genes related to innate immune signaling and nuclear factor-kappa B (NF-κB) in peripheral blood mononuclear cells (PBMCs) was associated with antidepressant response [16]. In our recently completed randomized, double-blind, placebo controlled, clinical trial evaluating infliximab for the treatment of bipolar depression, we identified early life trauma (i.e., childhood physical abuse) as a predictor of response [15]. Replicated evidence indicates that early childhood adversity is associated with elevated peripheral immuno-inflammatory activity in adulthood [17,18]. However, no studies so far have directly investigated neuroinflammatory processes in this population, nor potential mechanistic changes related to a therapeutic intervention.

A methodological challenge for the study of inflammation in brain disorders in humans has been the tenuous link between biomarkers and brain biochemistry and pathology. The majority of studies have used peripheral biomarkers to proxy brain processes, relying on the assumption that peripheral and brain immune activation are correlated (or that peripheral measures are reliable indicators of central processes), which has important limitations. A recent innovation is the use of blood extracellular vesicles (EVs) enriched for neuronal origin (NEVs) as a source of biomarkers that directly reflect neuronal-specific processes [19–23]. Extracellular vesicles (including exosomes) are membranous particles that are continuously released by virtually all cells, including neurons [24]. They can cross the blood–brain barrier and be preferentially isolated from peripheral blood, through immunocapture with antibodies against neuronal markers, most commonly L1 Cell Adhesion Molecule (L1CAM), a procedure that offers a multi-fold enrichment in neuronal cargo [19–23]. Extracellular vesicles contain cargo that reflects the content of the vesicle’s cellular origin, providing a novel avenue for
probing intracellular signaling processes including neuroinflammatory pathways that are putatively implicated in neuropsychiatric disorders. This methodology has been used to directly assess neuronal inflammatory biomarkers in mild traumatic brain injury [25,26], as well as biomarkers from other pathways in disparate conditions, such as Alzheimer’s disease (AD) and schizophrenia [27,28]. In addition, NEVs have been used as a source of biomarkers that predict neuronal-specific molecular target engagement and response to experimental treatments in clinical trials (e.g., in Parkinson’s disease [21], AD [29], and cancer [30]), revealing concerted engagement of entire signaling pathways.

We therefore aimed to investigate the neuroinflammatory mediators of response to infliximab in individuals with bipolar depression. We focused herein on the TNF receptors (TNFR) 1 and 2 and the NF-κB pathway, given its role as effectors of TNF-α signaling and downstream transcriptional response, as well as previously published work on the molecular effects of TNF-α antagonists [16,31–33]. Our primary hypothesis was that NEVs of infliximab-treated compared to placebo-treated participants would display changes in levels of TNFR/NF-κB signaling effectors, in association with antidepressant response. Based on the results of this controlled clinical trial of infliximab in bipolar depression [15], it is also an a priori hypothesis that a history of childhood abuse would moderate infliximab’s effects on TNFR/NF-κB pathway biomarkers. A secondary, exploratory hypothesis was that changes in TNFR/NF-κB pathway biomarkers would be associated with changes in global cortical thickness.

2. Materials and Methods

2.1. Study Design

The clinical study was a 12-week randomized, double-blind, placebo-controlled, parallel-group, fixed-dose trial evaluating the efficacy, safety, and tolerability of adjunctive infliximab for the treatment of individuals with bipolar I/II depression meeting inflammatory criteria [15]. The study was approved by the Institutional Ethics Board at the University Health Network, Toronto, ON, Canada, as well as Stanford University, Palo Alto, California. The study is registered with ClinicalTrials.gov (Identifier: NCT02363738 5 January 2015).

2.2. Participants

Eligible participants were male and female outpatients between the ages of 18 and 65 who met Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for a current major depressive episode as part of bipolar I/II disorder. All subjects provided written informed consent after receiving a complete description of the study. The diagnosis of BD was confirmed using the Mini-International Neuropsychiatric Interview (M.I.N.I.) 5.0.0 for the DSM-IV-TR and interview responses were compared to DSM-5 diagnostic criteria to confirm BD I/II diagnosis. A total score of 22 or higher on the Montgomery-Asberg Depression Rating Scale (MADRS) and a total score of less than 12 on the Young Mania Rating Scale (YMRS) was required for inclusion in the study. Participants were not excluded based on their past or current psychiatric medication history. The study sample was enriched for an inflammatory phenotype, according to criteria described in McIntyre et al. [15]. Briefly, participants were required to exhibit pre-treatment biochemical (i.e., peripheral CRP level ≥ 5 mg/L) and/or phenotypic (e.g., comorbid inflammatory bowel disorder, rheumatologic disorder or metabolic syndrome) evidence of inflammatory activation.

2.3. Procedures

Participants were enrolled at the Mood Disorders Psychopharmacology Unit (MDPU) in Toronto and Stanford University in Palo Alto between October 2015 and April 2018. Only individuals enrolled at the MDPU site had blood samples taken and composed the sample analyzed herein. All participants meeting eligibility criteria at screening were randomized to either receive intravenous infliximab (5 mg/kg) or placebo (saline solution matched to infliximab in color and consistency) administered adjunctively to their existing guideline-congruent pharmacologic regimen for BD. Eligible participants
were required to maintain their medication regimen during the 4 weeks before study enrollment and throughout the course of the 12-week study.

The infliximab dose and infusion schedule selected for this study were adopted from the protocol of a previously published interventional clinical trial with infliximab [14]. Participants received an infusion of infliximab (5 mg/kg) or placebo, administered over a period of 120 min by a rheumatology infusion registered nurse, at weeks 0 (baseline), 2, and 6. All participants completed the baseline infusion within one month of completing the screening assessment. Infliximab and placebo were prepared and dispensed in a concealed 250 mL infusion bag matched in color and consistency by hospital pharmacists who did not have contact with any of the participants. The randomization schedule was computer generated in blocks of 6 by a research team member who had no contact with the participants.

2.4. Clinical Measures

Participants, outcome assessors, principal investigators, and infusion nurses were all blinded to treatment randomization. Self-reported childhood maltreatment (i.e., Childhood Trauma Questionnaire [CTQ]) was measured at baseline. The CTQ is a 28-item test that measures 5 types of maltreatment—emotional, physical, and sexual abuse, and emotional and physical neglect. Based on previous findings published by McIntyre et al. [15], only the CTQ total score and the subdomain of physical abuse (PA) were used, both as continuous variables. Depressive symptoms severity was measured using the MADRS at every study visit.

2.5. Neuroimaging

High resolution 3D T1-weighted images were acquired from 14 participants from the placebo cohort and 13 participants from the infliximab group. Patients were scanned at two time points in the study, first at week 0 (baseline) prior to receiving any infusions and then again at week 12. Images were obtained on a General Electric Signa HDxt 1.5-Tesla scanner at Toronto General Hospital in Toronto, Ontario, Canada. The scanning parameters for the 3D T1-weighted fast spoiled gradient echo sequence were as follows: slice thickness = 1 mm, repetition time = 10.74 ms, echo time = 4.20 msec, inversion time = 450 msec, matrix size = 256 mm × 256 mm, field of view = 220 mm, flip angle = 15°, voxel size = 0.86 × 0.85 × 1 mm³, and scan duration = 15 min 3 s. There was a total of 146 slices produced in the axial plane.

Reconstruction of patient cortical tissue was performed using the Freesurfer (v6.0) imaging analysis suite, which is freely available online (https://surfer.nmr.mgh.harvard.edu/). The technical details of the procedures are described in prior publications [34,35]. Given that patients were scanned at two separate time points, images were automatically processed using the longitudinal stream of Freesurfer in order to extract reliable thickness estimates [36]. First, images were cross-sectionally processed for each timepoint using the default pipeline. Briefly, the preprocessing involves correcting for motion and magnetic inhomogeneities, removing non-brain tissue, registering the images to Talairach space and segmenting the white and gray matter tissues. The boundary between white matter and gray matter (i.e., the white surface) is first calculated and then inflated to determine the boundary between gray matter and cerebral spinal fluid (i.e., the pial surface). Once completed, all time points for a single patient are used to create an unbiased within-subject template for each patient, which is then run again through the Freesurfer pipeline described above. In the final step, the processed template is used to resample the individual time points, which further reduces variability across time. The global cortical thickness was obtained from the ‘Mean Thickness’ variable outputted by Freesurfer v6.0. This variable is a calculation, in millimeters, of the total thickness below the pial surface subtracted by the total thickness below the white surface. Therefore, it measures the cortical thickness of only grey matter, found within the pial and white surfaces, within the left and right hemispheres [37]. Moreover, it excludes any subcortical volumes and the cerebellum. Global cortical thickness values
were then extracted from the output using the ‘aparcstats2table’ command and were analyzed in IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, NY, USA).

2.6. Isolation of Extracellular Vesicles Enriched for Neuronal Origin

All available plasma samples from the clinical study were used and all experimental procedures were conducted blindly. Venous blood draws were conducted between 7:00 a.m.–10:00 a.m. after a 12 h fasting at baseline, and weeks 2, 6, and 12. Blood was collected in EDTA polypropylene tubes and within 1 h centrifuged at 3000 rpm for 15 min at 4 °C; supernatant plasma was divided into 0.5 mL aliquots and stored at −80 °C until analysis, in accordance with guidelines for pre-analytical factors for blood collection and storage for future biomarker analysis [38,39]. Plasma aliquots were processed blindly by a National Institute on Aging investigators (FDP, SC, CNO) following the methods published by Mustapic et al. [22]. NEVs were immunocaptured from plasma by targeting the neuronal trans-membrane marker L1 Cell Adhesion Molecule (L1CAM), which is expressed in EVs, following a methodology extensively characterized by our group [19,20,22] and others [40–42]. To reduce contamination with soluble plasma proteins, concentrate plasma EVs and, thereby, improve the yield of immunoprecipitation, plasma was defibrinated using Thrombin (System Biosciences, Inc., Mountainview, CA, USA) and total EVs were sedimented with Exoquick™ (System Biosciences, Inc., Mountainview, CA, USA) according to the manufacturer’s instructions. Total EVs were re-suspended in 0.5 mL of Ultra-pure distilled water with the manufacturer-recommended concentration of protease and phosphatase inhibitors. To immunocapture L1CAM+ NEVs, the suspension was incubated for 1 h at 4 °C with 4 μg of mouse anti-human CD171 (L1CAM) biotinylated antibody (clone 5G3) (Thermo Scientific, Inc., Waltham, MA, USA), followed by incubation with 25 μL of Pierce™ Streptavidin Plus UltraLink™ Resin (Thermo Scientific, Inc., Waltham, MA, USA) for 30 min at 4 °C. After centrifugation at 800× g for 10 min at 4 °C and removal of supernatant, NEVs were eluted with 200 μL of 0.1 M glycine. Then, beads were sedimented by centrifugation at 4500× g for 5 min at 4 °C, and the supernatants containing NEVs were transferred to clean tubes. pH was immediately neutralized with 1 M tris-HCl, and samples underwent 2 freeze thaw cycles with M-PER™ protein extraction reagent (Thermo Scientific, Inc., Waltham, MA, USA) supplemented with protease and phosphatase inhibitors to lyse the NEVs. The final suspensions containing NEV proteins were stored at −80 °C. Samples were thawed and vortexed twice prior to protein measurements. An extensive report on reproducibility and quality control measures for the NEV isolation methodology, detailed characterization for NEVs (by Nanoparticle Tracking Analysis, Electron Microscopy, and Western Blot quantification of canonical EV markers), and multifaceted evidence for neuronal cargo enrichment was recently published and is not repeated here as redundant [20].

2.7. NEV Protein Quantification

We quantified phosphorylated NF-κB (Ser436), FADD (Ser194), IKKα/β (Ser177/Ser181) and IκBx (Ser32), as well as total protein levels of TNFR1 and c-Myc using the MILLIPEX® MAP 6-Plex NF-κB Magnetic Bead Signaling kit (cat. no. 48-630MAG) (EMD Millipore Corporation, Billerica, MA, USA). Plates were read using Luminex® 200™ System and the xPOTENT® acquisition software (Luminex Corporation, Austin, TX, USA). In addition, we measured TNFR2 using a MESO SCALE DISCOVERY® (MSD) electrochemiluminescence plate assay (K151BC), read using a MESO QuickPlex SQ120 imager and the workbench Software 4.0 (Meso Scale Discovery, Rockville, MD, USA). Finally, we quantified Alix (or else human programmed cell death 6-interacting protein (PDCD6IP) (cat. no. CSB-EL017673HU) (Cusabio Biotech Co., LTD, Houston, TX, USA), an established EV marker enriched in exosomes [42,43], to assess differential NEV yield. Alix plates were read using the Synergy™ H1 microplate reader set to 450 nm and the Gen5™ microplate data collection software (BioTek Instruments, Winooski, VT, USA). The optimum dilution for each assay was determined using serial dilutions of test samples. For Alix, lysed NEVs were diluted 1:4 with the supplied sample diluent. No other assay required sample dilution. For TNFR2 and Alix assays, the concentration was determined using a standard curve.
separately for each plate using standards provided by the manufacturer and the four-parameter logistic regression curve-fit. For phospho-protein assays, a standard curve could not be constructed and thus we analyzed the electrochemiluminescence signal for MSD phospho-assays and the fluorescence signal for the Milliplex panel.

All assays were conducted in duplicate and the mean coefficients of variation (CV) across plates were 6.72% (TNFR2), 12.98% (NF-κB), 12.65% (FADD), 14.33% (IKKα/β), 14.51% (IκBα), 13.50% (TNFR1), 12.54% (c-Myc), and 4.29% (Alix). Duplicate NEV isolates from a healthy participant were included as internal control (IC) on every plate to assess between-plate variability. The CVs for the IC were: 10.57% (TNFR2), 8.54% (NF-κB), 11.38% (FADD), 14.49% (IKKα/β), 10.55% (IκBα), 10.37% (TNFR1), 10.62% (c-Myc), and 39.93% (Alix). Therefore, between-plates CVs for the IC for all analytes were under 20%, except for Alix, likely due to procuring kits from different lots. The IC was used to determine a correction factor (IC signal for a given plate divided by the average of IC signals in all plates), which was used to normalize raw signals from each plate.

The limit of detection (LOD), defined as mean of the blank plus 2.5 the standard deviation (SD) of the blank, was calculated from the electrochemiluminescence signal for MSD phospho-assays, fluorescence signal for the Milliplex panel, and colorimetric signal for the Alix ELISA. The LOD was: 3.03 ng/mL for TNFR2, 48.16 for NF-κB, 52.68 for FADD, 46.42 for IκBα, 34.04 for IκBα, 34.43 for TNFR1, 53.11 for c-Myc, and 168.71 ng/mL for Alix. The lowest limit of quantification (LLOQ) (defined as the concentration of the standard with: (1) signal above the LOD, (2) CV among duplicates <15%, and (3) recovery >80% and <120%), was calculated for each plate for TNFR2 and Alix assays, and the mean LLOQ was used as the global LLOQ. The LLOQ was 10.27 ng/mL for TNFR2, and 293.78 ng/mL for Alix.

Even though CVs of NEV samples from the same isolation run in duplicate were <15% for all biomarkers, to be even more conservative in our analysis, we identified and excluded the samples that had CVs of duplicates ≥15%, separately for each assay (17 samples for TNFR2, 35 samples for NF-κB, 32 samples for FADD, 32 samples for IκBα, 37 samples for IκBα, 34 samples for TNFR1, 30 samples for c-Myc, and 5 samples for Alix). Therefore, reported results are likely a conservative underestimation of true effect sizes, given the loss of power from excluding these values. Additional censoring criteria consisted of LLOQs for assays that had standard curve. For Alix, all samples were above the LLOQ and within the linear range of the standard curve. For TNFR2, 2 samples were below the LLOQ and above the LOD, but were excluded from the analysis as they had a CV ≥15%. For MSD phospho-assays and MILLIPLEX® 6-Plex, given that no standard curve was available, we excluded samples below the LOD: 1 for NF-κB, 10 for FADD, 1 for TNFR1, and 9 for c-Myc. TNFR2, IκBα, IκBα, and Alix did not have any sample below their respective LODs.

2.8. Statistical Analysis

To evaluate between-group differences in demographic baseline characteristics, non-parametric (i.e., Mann–Whitney U) and chi-square tests were used. A two-tailed alpha value of 0.05 was used to denote statistical significance. An intent-to-treat analysis (i.e., all participants who were randomized) was used to analyze changes over time of biomarkers’ levels. Biomarker values were natural log transformed to minimize skewness, but their distribution was still non-parametric. For baseline comparisons, generalized linear models were used, with linear, Poisson (for count data, e.g., MADRS scores), and gamma (for positively skewed distribution, e.g., serum CRP) distributions, as appropriate.

For the longitudinal analysis, due to the non-normal distribution of biomarkers and the clinical outcomes, generalized estimating equation (GEE) models were used. In analysis with biomarkers as an outcome, the best fit was found with gamma distribution with log link specification and an exchangeable covariance structure. For analyses with MADRS as the outcome, negative binomial models with log link specification and autoregressive covariance structure (AR-1) were selected. The independent variables were treatment group (i.e., infliximab vs. placebo), time (as a categorical variable), and the treatment × time interaction. The potential moderating effects of baseline self-reported childhood PA
were also analyzed (e.g., treatment \times time \times childhood \text{PA}), in separate models. Due to the nonlinearity of the models, the estimated $\beta$ coefficients were transformed into rate ratio (RR) estimates. No interim analysis was conducted.

3. Results

3.1. Demographics and Clinical Characteristics

A total of 55 participants were randomized at the MDPU site and were included in the analysis herein. Baseline sociodemographic and clinical characteristics of the intent-to-treat population are described in Table 1. There were no statistically significant demographic or clinical differences between groups. Twenty-four of 27 participants (88.8%) randomized to infliximab and 23/28 participants (85.7%) randomized to placebo received all three infusions. A total of 43 participants (78.2%) completed all 12 weeks; differences in study completion rates between treatment groups in this subsample were not statistically significant ($p = 0.469$). There were numerical, but not statistically significant (all $p > 0.1$), differences in biomarkers (log transformed) at baseline between subjects in the infliximab and placebo groups.

| Baseline Characteristics | Placebo ($n = 28$) | Infliximab ($n = 27$) | $p$-Value |
|--------------------------|-------------------|---------------------|-----------|
| Age (years), mean (SD)   | 45.75 (10.28)     | 44.04 (11.55)       | 0.564 $^a$ |
| Gender (female), n (%)   | 24 (85.7)         | 20 (74.1)           | 0.281 $^b$ |
| Ethnicity (Caucasian), n (%) | 5 (17.9)   | 4 (14.8)            | 0.760 $^b$ |
| Education, n (%)         |                   |                     |           |
| High school              | 4 (14.8)          | 5 (19.2)            |           |
| College/University       | 22 (81.5)         | 17 (65.4)           |           |
| Graduate school          | 1 (3.7)           | 4 (15.4)            |           |
| MADRS (total score), mean (SD) | 30.07 (6.72) | 31.33 (6.85)       | 0.595 $^c$ |
| YMRS (total score), mean (SD) | 4.71 (4.30)  | 3.48 (3.08)        | 0.377 $^c$ |
| BMI (kg/m$^2$), mean (SD) | 34.55 (7.66)    | 34.57 (10.08)      | 0.608 $^c$ |
| Tobacco use, n (%)       | 8 (28.6)          | 10 (37.0)           | 0.504 $^b$ |
| Age at onset (years), mean (SD) | 17.14 (9.32) | 18.59 (8.13)      | 0.437 $^c$ |
| Number of lifetime psychiatric hospitalizations, mean (SD) | 1.58 (2.02) | 1.74 (1.91) | 0.679 $^c$ |
| Length of current depressive episode (months), mean (SD) | 11.67 (20.80) | 11.85 (15.48) | 0.378 $^c$ |
| Medications              |                   |                     |           |
| Antipsychotic, n (%)     | 16 (66.7)         | 18 (69.2)           | 0.846 $^b$ |
| Antidepressant, n (%)    | 18 (75.0)         | 15 (57.7)           | 0.197 $^b$ |
| Lithium, n (%)           | 5 (20.8)          | 6 (22.0)            | 0.904 $^b$ |
| Anticonvulsants, n (%)   | 10 (41.7)         | 15 (57.7)           | 0.258 $^b$ |
| Antidiabetic, n (%)      | 4 (14.3)          | 4 (14.8)            | 0.956 $^b$ |
| Childhood Trauma Questionnaire (total score), mean (SD) | 54.46 (17.81) | 56.51 (22.54) | 0.866 $^c$ |
| Physical Abuse, mean (SD) | 9.35 (5.61)     | 8.48 (5.67)        | 0.266 $^c$ |

$^a$ t-test; $^b$ chi-square; $^c$ Mann-Whitney U.

3.2. Baseline Associations between NEV Biomarkers and Clinical Variables

There were no associations between age, sex, BMI, and use of tobacco and NEV biomarkers levels at baseline (all $p > 0.1$). Use of psychotropic or antidiabetic medications was also not associated with any biomarker (all $p > 0.1$). After adjustment for potential confounders, there were significant
associations between biomarkers, MADRS and CRP, but no association between biomarkers and CTQ scores (Table 2).

Table 2. Associations between NEV biomarkers and Montgomery–Asberg Depression Rating Scale (MADRS), C-reactive protein (CRP), and Childhood Trauma Questionnaire (CTQ), at baseline.

| NEV     | MADRS   | CRP     | CTQ Total Score |
|---------|---------|---------|-----------------|
|         | RR      | p-Value | RR             | p-Value | RR | p-Value |
| TNFR1   | 0.944   | 0.014   | 1.176           | 0.026   | 1.002 | 0.955   |
| TNFR2   | 1.097   | 0.110   | 2.021           | <0.001  | 1.190 | 0.072   |
| NF-kB   | 0.954   | 0.015   | 1.166           | 0.011   | 1.047 | 0.156   |
| c-Myc   | 0.961   | 0.100   | 1.178           | 0.026   | 1.042 | 0.288   |
| FADD    | 0.962   | 0.098   | 1.217           | 0.007   | 1.067 | 0.094   |
| IKKα/β  | 0.965   | 0.226   | 1.385           | <0.001  | 1.048 | 0.346   |
| IκBx    | 0.941   | 0.056   | 1.389           | <0.001  | 1.080 | 0.136   |

<sup>a</sup> Generalized linear model with Poisson distribution, adjusted for age, gender, and Alix concentration; <sup>b</sup> Generalized linear model with gamma distribution, adjusted for age, gender, and Alix concentration; <sup>c</sup> Generalized linear model with gamma distribution, adjusted for age, gender, MADRS total score, and Alix concentration.

3.3. Association of Infliximab with NEV Biomarker Changes

We initially assessed changes in NEV biomarkers over time in models adjusted only for Alix concentration, a canonical EV marker, to normalize for differential EV yield. There was no significant treatment by time interaction for any biomarker (all ps > 0.1). There was an effect of time only for TNFR2 ($\chi^2 = 8.419$, df = 3, $p = 0.038$), which showed an increase in levels in all subjects.

Subsequently, we conducted separate analyses to determine whether changes in NEV biomarkers were moderated by baseline PA as hypothesized a priori. There were moderating effects of PA on treatment by time interactions for TNFR1 ($\chi^2 = 9.275$, df = 3, $p = 0.026$), NF-kB ($\chi^2 = 13.825$, df = 3, $p = 0.003$), and IκBx ($\chi^2 = 7.990$, df = 3, $p = 0.046$). These models also indicated that there were significant treatment by time interactions for TNFR1 ($\chi^2 = 10.305$, df = 3, $p = 0.016$), NF-kB ($\chi^2 = 9.095$, df = 3, $p = 0.028$) and IκBx ($\chi^2 = 7.900$, df = 3, $p = 0.048$).

For TNFR1 levels, higher levels of PA were associated with larger decreases in infliximab-treated participants, relative to placebo, at week 2 (RR = 0.999, df = 1, $p = 0.026$), week 6 (RR = 0.987, df = 1, $p = 0.009$), and week 12 (RR = 0.983, df = 1, $p = 0.003$). Higher levels of PA were also associated with larger decreases in NF-kB levels in infliximab-treated participants, relative to placebo at week 6 (RR = 0.986, df = 1, $p = 0.022$) and week 12 (RR = 0.994, df = 1, $p < 0.001$), but not at week 2 (RR = 0.998, df = 1, $p = 0.197$). Similarly, larger decreases in IκBx levels in infliximab-treated participants, relative to placebo, were observed at week 12 (RR = 0.985, df = 1, $p = 0.006$), but not week 2 (RR = 0.995, df = 1, $p = 0.2056$) or week 6 (RR = 0.993, df = 1, $p = 0.161$).

Figure 1 illustrates the difference between placebo versus infliximab based on analysis of subgroups using the CTQ dichotomous clinical cut-off score that differentiates between the presence or absence of significant PA (i.e., $\geq 8$) (16). There were no moderating effects of PA on treatment by time for c-Myc, FADD, IKKα/β, or TNFR2 (all ps > 0.1).

3.4. Moderation of Clinical Effect by NEV Biomarkers

Treatment effect on depressive symptom severity was previously reported. The biomarkers that were shown to change over time were then assessed as moderators of changes in depressive symptom severity. We observed a significant time by treatment by TNFR1 interaction on MADRS scores ($\chi^2 = 7.997$, df = 3, $p = 0.046$). In infliximab-treated patients, decreases in TNFR1 levels were associated with decreases in MADRS scores, more strongly at week 6 (RR = 0.672, df = 1, $p = 0.005$) than week 2 (RR = 0.849, df = 1, $p = 0.985$) or week 12 (RR = 0.801, df = 1, $p = 0.128$) (Figure 2). No other biomarker moderated changes in depressive symptoms.
Figure 1. Least squares mean changes in biomarkers levels from baseline to week 12 in infliximab-or placebo-treated individuals with bipolar disorder with or without clinically significant history of physical abuse (PA). Results from an intent-to-treat generalized estimating equation analysis of 55 participants with bipolar disorder who were administered three infusions of infliximab (n = 27) or placebo (n = 28) at baseline and at weeks 2 and 6 of a 12-week trial. Error bars indicate standard errors (SE). Abbreviations: TNFR1: Tumour necrosis factor-alpha receptor-1; NF-κB: nuclear factor-kappa B; PA: with clinically significant history of physical abuse; No PA: without clinically significant history of physical abuse.

Figure 2. Association between changes in TNFR1 levels, adjusted for Alix concentration, and changes in MADRS scores, in the placebo and infliximab treated groups, at week 6.
3.5. Change in NEV Biomarkers and Cortical Thickness

In the subsample that underwent neuroimaging (n = 27), there were no baseline differences in age (p = 0.638), sex (p = 0.496), and MADRS total score (p = 0.720). Longitudinal analysis, adjusted for age and sex, indicated a trend for an increase in global cortical thickness in the infliximab group (treatment by time interaction: χ² = 2.817, df = 1, p = 0.093). Changes in TNFR1 levels were associated with increased global cortical thickness in infliximab- (r = −0.581, p = 0.029) but not placebo-treated patients (r = 0.196, p = 0.501) (Figure 3). Changes in NF-κB or IkBα were not associated with change in global cortical thickness in both groups (all ps > 0.5).

![Figure 3](image-url)

**Figure 3.** Association between changes in TNFR1 levels, adjusted for Alix concentration, and changes in cortical thickness, in the placebo and infliximab treated groups, at endpoint.

4. Discussion

Herein, we leveraged circulating NEV biomarkers to show that infliximab engaged its target TNFR/NF-κB neuro-inflammatory pathway in individuals with BD, and that the molecular engagement in neurons was associated with clinical response and neurostructural changes. Interestingly, our results suggest that infliximab treatment resulted in inhibition of TNFR/NF-κB signaling in an early life trauma-dependent manner, similar to the overall effects in this clinical trial. Results from preclinical and clinical studies have consistently documented that TNF antagonists modulate NF-κB activity in diverse tissues [31,44–48]. TNF-α is a pro-inflammatory cytokine that exerts its effects by binding to two cell-surface receptors (TNFRs 1 and 2), which, through activation of downstream mediators,
result in activation of NF-κB. Consequently, and consistently with our results, infliximab’s antagonism of TNF-α has been associated with downregulation of TNFRs, decreased activity of NF-κB, as well as of the mediators FADD, IKKa/β and IkBα. Although specific neuronal effects of TNF-α antagonists were previously shown in animal models [49,50], to the best of our knowledge, this is the first report of molecular effects in neurons of living humans using NEV isolation and analysis. We show that the NEV content of NF-κB signaling mediators downstream from TNFR are preferentially altered in the subset of infliximab-treated BD patients that also shows clinical response. This could be interpreted as a result of preferential engagement of the TNFα-TNFR-NF-κB signaling cascade in neurons of these patients and/or due to a preferential systemic response to infliximab, which also affects the neuronal response to it. Either way, neuronal signaling is the likely proximate cause of the clinical effect, and this is reflected as a differential change in NEV biomarkers.

Previous studies have documented an association between early life stress and increased NF-κB activation in PBMCs from individuals with major depressive disorder [51] and women with post-traumatic stress disorder [52], although in both studies NF-κB activity was more strongly correlated with symptom severity than with measures of childhood trauma. However, a separate study reported increased NF-κB activity following stimulation with lipopolysaccharides in PBMCs from adolescents exposed to childhood maltreatment, but without psychopathology, relative to controls with no history of trauma [53]. We did not observe an association between NEV biomarkers from the NF-κB pathways and CTQ scores at baseline. Nonetheless, our results were consistent with findings from the clinical trial, insofar as history of childhood maltreatment (i.e., physical abuse) predicted larger reductions in NF-κB pathway biomarkers in infliximab-treated participants, relative to placebo. These results support the hypothesis that neuroinflammation is a relevant pathophysiological mechanism connecting early life stress to BD, as well as a target for therapeutic interventions. Contrary to previously published work [54], we observed a negative association between NF-κB biomarkers and depressive symptoms severity at baseline. Of note, all participants had MADRS total scores of at least 22, indicating at least moderate depression, thus our study was not powered to reliably detect baseline associations between symptom severity and biomarker levels.

We also documented that changes in NEV TNFR1 levels moderated the antidepressant response to infliximab. In infliximab-treated participants, reductions in TNFR1 levels were associated with improvement of depressive symptoms, an effect that was not detected in the placebo group. Higher plasma levels of soluble TNFR1 have been consistently shown in BD [6,55–59]. Moreover, evidence indicates that increased plasma levels of soluble TNFR1 are associated with neurostructural abnormalities (e.g., reduction in hippocampal and gray matter volumes) in individuals with BD [6] and major depressive disorder [60]. Accumulating evidence indicates that TNFR-mediated TNF-α signaling is a key regulator of neuronal plasticity [61–63], particularly of synaptic scaling, which regulates the excitatory drive during chronic inactivity or hyperactivity [64,65]. In addition, evidence from preclinical studies indicates that activation of TNFR1 mainly leads to apoptosis and inflammation, whereas, in contrast, TNFR2 signaling mediates a homeostatic effect, including cell survival and regeneration [65,66]. While studies have documented that there is a complex interaction between TNFR1 and TNFR2, which seems to depend on many contextual factors (e.g., cell type, intracellular or extracellular environment), a reduction of TNFRI activity within the context of preserved TNFR2 signaling could also shift the balance in favor of cellular survival [63,67–71]. Consistently with this hypothesis, we observed an association between reduction in TNFRI levels in NEVs and increase in global cortical thickness in infliximab-treated participants. Thus, infliximab-induced effects on synaptic plasticity and neuronal excitability is one plausible mechanism to explain its antidepressant and neurostructural effects.

The current study also adds to the literature demonstrating the potential use of NEVs harvested from peripheral blood as a source of biomarkers to investigate target engagement and molecular responses to therapeutic interventions in clinical trials for neuropsychiatric disorders. There is evidence that neurons exposed to TNF-α release more EVs [72], suggesting that TNF-α regulates EV
biogenesis and, potentially, that infliximab treatment could decrease the abundance of NEVs in plasma. However, in our study, we did not see an infliximab effect on NEV levels of Alix, an intra-vesicular EV marker, suggesting that, whatever effects infliximab might have had on neurons, it did not alter the levels of circulating NEVs. Moreover, the concentration of each NEV biomarker was normalized to that of Alix. Therefore, any biomarker differences observed cannot be attributed to an infliximab-induced change in NEV load between samples. Previously published work has used EVs to assess changes in biomarkers of brain insulin signaling in clinical trials of a protein restriction diet for prostate cancer [30], exenatide for PD [21], and intranasal insulin for AD [29]. This is the first NEV study focused on a neuro-inflammatory pathway in a mood disorders’ population, broadening the scope, and providing further support for the utility of NEVs as outcomes in clinical trials in neurology and psychiatry.

This study’s strengths include a participant population enriched for disturbed immune-inflammatory homeostasis, using biochemical and phenotypic criteria [15]. Although the immune-inflammatory criteria were heterogeneous, the resulting sample was more homogenous, and likely more powered to detect relevant effects of inflammatory processes, compared to the typical clinical samples of BD, composed usually of participants recruited solely based on current symptom severity. The convergent results vis-à-vis the modulatory effect of childhood maltreatment on a biological system, herein hypothesized a priori, informed by the results of this controlled clinical trial, reinforces the validity of these findings. Finally, this study’s longitudinal design and use of a therapeutic agent with a well-known biological target and a technique that allows for the direct measurement of molecular mediators in neuronal cells provides robust evidence regarding the role of neuroinflammatory processes in the pathophysiology, and potentially in the treatment, of BD.

Limitations include a relatively small sample size (n = 55), which makes the study unlikely to have been sufficiently powered to detect smaller effect sizes, and recruitment from a tertiary care clinic, which might limit its applicability to community samples. We also included participants receiving complex and mixed pharmacotherapy regimens; although we did not detect an association between specific agents and biomarkers levels, we could not completely rule out potential confounding effects. Moreover, our approach to NEV isolation has some limitations. We used immunoprecipitation targeting L1CAM, which has been widely accepted as a neuronal marker suitable for positive selection of NEVs due to its high expression by brain neurons (e.g., see recent publications by multiple groups [19,20,40,41]); however, it is also widely recognized that L1CAM is not exclusive to neurons (see https://www.proteinatlas.org/ENSG00000198910-L1CAM/tissue). Given that NF-κB signaling is also not specific to neurons, the potential contribution of non-neuronal but L1CAM+ EVs to the isolated EV subpopulation raises the possibility that the effects of infliximab on biomarkers cannot be solely attributable to neurons.

In conclusion, the results of this NEV biomarker study based on a randomized, placebo-controlled clinical trial indicates that infliximab engages its hypothesized neuronal target, in a trauma-dependent manner and in association with biologically and clinically meaningful results. This is the first study using NEVs to investigate the TNFR1/NF-κB pathway in neurons of living humans, as well as the potential neural effects of TNF-α antagonism, in individuals with BD. The evidence described herein can inform disease models of neuropsychiatric disorders centered on and/or involving neuroinflammatory mechanisms, in addition to providing further insights on the long-term clinical and biological effects of childhood maltreatment.

Author Contributions: R.B.M. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: R.B.M., Y.L., J.D.R., E.B., T.S., R.S.M. and D.K. Acquisition, analysis, or interpretation of clinical data: R.B.M., M.S., Y.L., M.I., N.R., V.E.C., N.E.K., T.S. and R.S.M. Acquisition, analysis, or interpretation of biomarker data: R.B.M., F.D.-P., S.C., C.N.-O., R.S.M. and D.K. Drafting of the manuscript: R.B.M., F.D.-P., R.S.M. and D.K. Critical revision of the manuscript for important intellectual content: J.D.R., E.B., T.S. and C.L.R. Statistical analysis: R.B.M. Obtained funding: R.B.M., R.S.M. and D.K. Administrative, technical, or material support: M.S., Y.L., V.E.C., R.S.M. and D.K. Supervision: R.S.M. and D.K. All authors have read and agreed to the published version of the manuscript.
**Funding:** This study was supported in part by grant 13T-012 from the Stanley Medical Research Institute and in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (NIH). The Stanley Medical Research Institute and the National Institute on Aging had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The final manuscript underwent internal clearance prior to submission according to NIH regulations for Intramural Research Program investigators. Rodrigo Mansur reported receiving funding from the Academy of Schizophrenia Research, Department of Psychiatry, University of Toronto, outside the submitted work. Roger McIntyre reported receiving grants from Stanley Medical Research Institute during the conduct of the study; receiving grants from the Canadian Institutes of Health Research/Global Alliance for Chronic Diseases/Chinese National Natural Research Foundation outside the submitted work; and receiving speaking/consultation fees from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, and Minerva outside the submitted work. Mehala Subramaniappilai reported receiving grants from Stanley Medical Research Institute during the conduct of the study. Elisa Brietzke reported receiving personal fees from Daiichi Sankyo and receiving grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo Research Foundation, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Southeastern Ontario Academic Medical Organization and L’Oreal forWomen in Science Award outside the submitted work. Trisha Suppes reported receiving grants from Stanley Medical Research Institute during the conduct of the study and from the National Institute on Drug Abuse, the National Institutes of Health, National Institute of Mental Health, Palo Alto Health Sciences, Pathway Genomics, and VA Cooperative Studies Program; receiving personal and nonfinancial support from CMologe, Global Medical Education, and Sunovion Pharmaceuticals, Inc; and receiving personal fees from Allergan Inc., Hogrefe Publishing, Jones and Bartlett, Medscape Education, and UpToDate. Dr. Raison is director of Clinical and Translational Research for Usona Institute and serves as a consultant to Usona Institute, Emory Healthcare, Allermes and Novartis, outside the submitted work.

**Acknowledgments:** This study was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Munkholm, K.; Brauner, J.V.; Kessing, L.V.; Vinberg, M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. *J. Psychiatr. Res.* 2013, 47, 1119–1133. [CrossRef] [PubMed]

2. Dargel, A.A.; Godin, O.; Kapczinski, F.; Kuper, D.J.; Leboyer, M. C-reactive protein alterations in bipolar disorder: A meta-analysis. *J. Clin. Psychiatry* 2015, 76, 142–150. [CrossRef] [PubMed]

3. Giridharan, V.V.; Sayana, P.; Pinjari, O.F.; Ahmad, N.; da Rosa, M.L.; Quevedo, J.; Barichello, T. Postmortem evidence of brain inflammatory markers in bipolar disorder: A systematic review. *Mol. Psychiatry* 2020, 25, 94–113. [CrossRef] [PubMed]

4. Haarman, B.C.; Riemersma-Van der Lek, R.F.; de Groot, J.C.; Ruhe, H.G.; Klein, H.C.; Zandstra, T.E.; Burger, H.; Schoevers, R.A.; de Vries, E.F.; Drexhage, H.A.; et al. Neuroinflammation in bipolar disorder—A [(11)C]-R-PK11195 positron emission tomography study. *Brain Behav. Immun.* 2014, 40, 219–225. [CrossRef]

5. Wang, A.K.; Miller, B.J. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder, and depression. *Schizophr. Bull.* 2018, 44, 75–83. [CrossRef]

6. Tsai, S.Y.; Gildengers, A.G.; Hsu, J.L.; Chung, K.H.; Chen, P.H.; Huang, Y.J. Inflammation associated with volume reduction in the gray matter and hippocampus of older patients with bipolar disorder. *J. Affect. Disord.* 2019, 244, 60–66. [CrossRef]

7. Lin, K.; Shao, R.; Wang, R.; Lu, W.; Zou, W.; Chen, K.; Gao, Y.; Brietzke, E.; McIntyre, R.S.; Mansur, R.B.; et al. Inflammation, brain structure and cognition interrelations among individuals with differential risks for bipolar disorder. *Brain Behav. Immun.* 2020, 83, 192–199. [CrossRef]

8. Benedetti, F.; Poletti, S.; Hoogenboezem, T.A.; Mazza, E.; Ambree, O.; de Wit, H.; Wijkhuijs, A.J.; Locatelli, C.; Bollettini, I.; Colombo, C.; et al. Inflammatory cytokines influence measures of white matter integrity in Bipolar Disorder. *J. Affect. Disord.* 2016, 202, 1–9. [CrossRef]

9. Chung, K.H.; Huang, S.H.; Wu, J.Y.; Chen, P.H.; Hsu, J.L.; Tsai, S.Y. The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. *Neuropsychobiology* 2013, 68, 168–173. [CrossRef]

10. Savitz, J.; Dantzer, R.; Wurfel, B.E.; Victor, T.A.; Ford, B.N.; Bodurka, J.; Bellgowan, P.S.; Teague, T.K.; Drevets, W.C. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively...
associated with hippocampal and amygdalar volume in bipolar disorder. *Psychoneuroendocrinology* 2015, 52, 200–211. [CrossRef]

11. Husain, M.I.; Strawbridge, R.; Stokes, P.R.; Young, A.H. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. *J. Psychopharmacol.* 2017, 31, 1137–1148. [CrossRef] [PubMed]

12. Rosenblat, J.D.; Kakar, R.; Berk, M.; Kesing, L.V.; Vinberg, M.; Baune, B.T.; Mansur, R.B.; Brietzke, E.; Goldstein, B.I.; McIntyre, R.S. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis. *Bipolar Dis.* 2016, 18, 89–101. [CrossRef]

13. Kappelmann, N.; Lewis, G.; Dantzer, R.; Jones, P.B.; Khandaker, G.M. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. *Mol. Psychiatry* 2018, 23, 335–343. [CrossRef] [PubMed]

14. Raison, C.L.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. *JAMA Psychiatry* 2013, 70, 31–41. [CrossRef] [PubMed]

15. McIntyre, R.S.; Subramaniapillai, M.; Lee, Y.; Pan, Z.; Carmona, N.E.; Shekotikhina, M.; Rosenblat, J.D.; Brietzke, E.; Soczynska, J.K.; Cosgrove, V.E.; et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: A randomized clinical trial. *JAMA Psychiatry* 2019, 76, 783–790. [CrossRef] [PubMed]

16. Mehta, D.; Raison, C.L.; Woolwine, B.J.; Haroon, E.; Binder, E.B.; Miller, A.H.; Felger, J.C. Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. *Brain Behav. Immun.* 2013, 31, 205–215. [CrossRef] [PubMed]

17. Baumeister, D.; Akhtar, R.; Ciufolini, S.; Pariante, C.M.; Mondelli, V. Childhood trauma and adulthood inflammation: A meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. *Mol. Psychiatry* 2016, 21, 642–649. [CrossRef]

18. Coelho, R.; Viola, T.W.; Wals-Bass, C.; Bietzke, E.; Grassi-Oliveira, R. Childhood maltreatment and inflammatory markers: A systematic review. *Acta Psychiatr. Scand.* 2014, 129, 180–192. [CrossRef]

19. Pulliam, L.; Sun, B.; Mustapic, M.; Chawla, S.; Kapogiannis, D. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer’s disease. *J. Neurovirol.* 2019, 25, 702–709. [CrossRef]

20. Kapogiannis, D.; Mustapic, M.; Shardell, M.D.; Berkowitz, S.T.; Diehl, T.C.; Spangler, R.D.; Tran, J.; Lazaropoulos, M.P.; Chawla, S.; Gulyani, S.; et al. Association of extracellular vesicle biomarkers with alzheimer disease in the baltimore longitudinal study of aging. *JAMA Neurol.* 2019, 76, 420–429. [CrossRef]

21. Athauda, D.; Gulyani, S.; Karnati, H.; Li, Y.; Tweedie, D.; Mustapic, M.; Chawla, S.; Chowdhury, K.; Skene, S.S.; Greig, N.H.; et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: A secondary analysis of the exenatide-PD trial. *JAMA Neurol.* 2019, 76, 420–429. [CrossRef] [PubMed]

22. Mustapic, M.; Eitan, E.; Werner, J.K., Jr.; Berkowitz, S.T.; Lazaropoulos, M.P.; Tran, J.; Goetzl, E.J.; Kapogiannis, D. Plasma extracellular vesicles enriched for neuronal origin: A potential window into brain pathologic processes. *Front. Neurosci.* 2017, 11, 278. [CrossRef] [PubMed]

23. Fiandaca, M.S.; Kapogiannis, D.; Mapstone, M.; Boxer, A.; Eitan, E.; Schwartz, J.B.; Abner, E.L.; Petersen, R.C.; Federo, H.J.; Miller, B.L.; et al. Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. *Alzheimers Dement.* 2015, 11, 600–607.e1. [CrossRef] [PubMed]

24. Faure, J.; Lachenal, G.; Court, M.; Hirringer, J.; Chatellard-Causse, C.; Blot, B.; Grange, J.; Schoehn, G.; Goldberg, Y.; Boyer, V.; et al. Exosomes are released by cultured cortical neurones. *Mol. Cell. Neurosci.* 2006, 31, 642–648. [CrossRef] [PubMed]

25. Goetzl, E.J.; Ledreux, A.; Granholm, A.C.; Elahi, F.M.; Goetzl, L.; Hiramoto, J.; Kapogiannis, D. Neuron-derived exosome proteins may contribute to progression from repetitive mild traumatic brain injuries to chronic traumatic encephalopathy. *Front. Neurol.* 2019, 13, 452. [CrossRef] [PubMed]

26. Gill, J.; Mustapic, M.; Diaz-Arrastia, R.; Lange, R.; Gulyani, S.; Diehl, T.; Motamedi, V.; Osier, N.; Stern, R.A.; Kapogiannis, D. Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel. *Brain Injury* 2018, 32, 1277–1284. [CrossRef]
27. Kapogiannis, D.; Boxer, A.; Schwartz, J.B.; Abner, E.L.; Biragyn, A.; Masharani, U.; Frassetto, L.; Petersen, R.C.; Miller, B.L.; Goetzl, E.J. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. *FASEB J.* 2015, 29, 589–596. [CrossRef]

28. Wijtenburg, S.A.; Kapogiannis, D.; Korenic, S.A.; Mullins, R.J.; Tran, J.; Gaston, E.E.; Chen, S.; Mustapic, M.; Hong, L.E.; Rowland, L.M. Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia. *Schizophr. Res.* 2019, 208, 324–330. [CrossRef]

29. Mustapic, M.; Tran, J.; Craft, S.; Kapogiannis, D. Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in Alzheimer’s disease. *J. Alzheimers Dis.* 2019, 69, 489–498. [CrossRef]

30. Eitan, E.; Hutchison, E.R.; Marosi, K.; Comotto, J.; Mustapic, M.; Nigam, S.M.; Suire, C.; Maharana, C.; Jicha, G.A.; Liu, D.; et al. Extracellular vesicle-associated abeta mediates trans-neuronal bioenergetic and Ca(2+)-handling deficits in Alzheimer’s disease models. *NPJ Aging Mech. Dis.* 2016, 2. [CrossRef]

31. Torices, S.; Julia, A.; Munoz, P.; Varela, I.; Balsa, A.; Marsal, S.; Fernandez-Nebro, A.; Blanco, F.; Lopez-Hoyos, M.; Martinez-Taboada, V.; et al. A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis. *Arthritis Res. Ther.* 2016, 18, 221. [CrossRef] [PubMed]

32. Kokolakis, G.; Giannikaki, E.; Stathopoulos, E.; Avramidis, G.; Tosca, A.D.; Kruger-Krasagakis, S. Infl iximab restores the balance between pro- and anti-apoptotic proteins in repressing psoriatic lesions. *Br. J. Dermatol.* 2012, 166, 491–497. [CrossRef] [PubMed]

33. Eggert, M.; Seeck, U.; Semmler, M.; Maass, U.; Dietmann, S.; Schulz, M.; Dotzlaw, H.; Neeck, G. An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: Imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration. *Rheumatol. Int.* 2007, 27, 841–846. [CrossRef] [PubMed]

34. Kokolakis, G.; Giannikaki, E.; Stathopoulos, E.; Avramidis, G.; Tosca, A.D.; Kruger-Krasagakis, S. Infl iximab restores the balance between pro- and anti-apoptotic proteins in repressing psoriatic lesions. *Br. J. Dermatol.* 2012, 166, 491–497. [CrossRef] [PubMed]

35. Eggert, M.; Seeck, U.; Semmler, M.; Maass, U.; Dietmann, S.; Schulz, M.; Dotzlaw, H.; Neeck, G. An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: Imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration. *Rheumatol. Int.* 2007, 27, 841–846. [CrossRef] [PubMed]

36. Reuter, M.; Schmansky, N.J.; Rosas, H.D.; Fischl, B. Within-subject template estimation for unbiased longitudinal image analysis. *Neuroimage* 2012, 61, 1402–1418. [CrossRef]

37. Fischl, B.; Dale, A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proc. Natl. Acad. Sci. USA* 2000, 97, 11050–11055. [CrossRef]

38. Wittwe, K.W.; Buzas, E.I.; Bemis, L.T.; Bora, A.; Lasser, C.; Lotvall, J.; Nolte-`t Hoen, E.N.; Piper, M.G.; Sivaraman, S.; Skog, J.; et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J. Extracell. Vesicles* 2013, 2. [CrossRef]

39. Coumans, F.A.W.; Brisson, A.R.; Buzas, E.I.; Dignat-George, F.; Drees, E.E.E.; El-Andaloussi, S.; Emanueli, C.; Gasecka, A.; Hendrix, A.; Hill, A.F.; et al. Methodological guidelines to study extracellular vesicles. *Circ. Res.* 2017, 120, 1632–1648. [CrossRef]

40. Agliardi, C.; Guerini, F.R.; Zanzottera, M.; Bianchi, A.; Nemni, R.; Clerici, M. SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s disease. *Mol. Neurobiol.* 2019, 56, 5792–5798. [CrossRef] [PubMed]

41. Shi, M.; Kovac, A.; Korff, A.; Cook, T.J.; Ginghina, C.; Bullock, K.M.; Yang, L.; Stewart, T.; Zheng, D.; Aro, P.; et al. C5s tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. *Alzheimers Dement.* 2016, 12, 1125–1131. [CrossRef] [PubMed]

42. Jia, L.; Qiu, Q.; Zhang, H.; Chu, L.; Du, Y.; Zhang, J.; Zhou, C.; Liang, F.; Shi, S.; Wang, S.; et al. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. *Alzheimers Dement.* 2019, 15, 1071–1080. [CrossRef] [PubMed]

43. Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J.P.; Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Thery, C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc. Natl. Acad. Sci. USA* 2016, 113, E968–E977. [CrossRef] [PubMed]

44. Hakim, M.S.; Ding, S.; Chen, S.; Yin, Y.; Su, J.; van der Woude, C.J.; Fuhler, G.M.; Peppelenbosch, M.P.; Pan, Q.; Wang, W. TNF-alpha exerts potent anti-rotavirus effects via the activation of classical NF-kappaB pathway. *Virus Res.* 2018, 253, 28–37. [CrossRef]

45. Samidurai, M.; Ramanamy, V.S.; Jo, J. beta-amyloid inhibits hippocampal LTP through TNFR/IKK/NF-kappaB pathway. *Neuro. Res.* 2018, 40, 268–276. [CrossRef]
46. Chengke, L.; Weiwei, L.; Xiyang, W.; Ping, W.; Xiaoyang, P.; Zhengquan, X.; Hao, Z.; Penghui, Z.; Wei, P. Effect of infliximab combined with methylprednisolone on expressions of NF-kappaB, TRADD, and FADD in rat acute spinal cord injury. *Spine* 2013, 38, E861–E869. [CrossRef]

47. Mahmoud, M.F.; El Shazly, S.M.; Barakat, W. Inhibition of TNF-alpha protects against hepatic ischemia-reperfusion injury in rats via NF-kappaB dependent pathway. *Naunyn Schmiedebergs Arch. Pharmacol.* 2012, 385, 465–471. [CrossRef]

48. Kanbe, K.; Inoue, K.; Inoue, Y.; Suzuki, Y. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. *Clin. Rheumatol.* 2008, 27, 777–781. [CrossRef]

49. Dadsetan, S.; Balzano, T.; Forteza, J.; Cabrera-Pastor, A.; Taoro-Gonzalez, L.; Hernandez-Rabaza, V.; Gil-Perotin, S.; Cubas-Nunez, L.; Garcia-Verdugo, J.M.; Agusti, A.; et al. Reducing peripheral inflammation with infliximab reduces neuroinflammation and improves cognition in rats with hepatic encephalopathy. *Front. Mol. Neurosci.* 2016, 9, 106. [CrossRef]

50. Pace, T.W.; Mletzko, T.C.; Alagbe, O.; Musselman, D.L.; Nemeroff, C.B.; Miller, A.H.; Heim, C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. *Am. J. Psychiatry* 2006, 163, 1630–1633. [CrossRef] [PubMed]

51. Pace, T.W.; Wingenfeld, K.; Schmidt, I.; Meinschmidt, G.; Hellhammer, D.H.; Heim, C.M. Increased peripheral NF-kappaB pathway activity in women with childhood abuse-related posttraumatic stress disorder. *Brain Behav. Immun.* 2012, 26, 13–17. [CrossRef] [PubMed]

52. do Prado, C.H.; Grassi-Oliveira, R.; Daruy-Filho, L.; Wieck, A.; Bauer, M.E. Evidence for immune activation and resistance to glucocorticoids following childhood maltreatment in adolescents without psychopathology. *Neuropsychopharmacology* 2017, 42, 2277–2282. [CrossRef] [PubMed]

53. Miklowitz, D.J.; Portnoff, L.C.; Armstrong, C.C.; Keenan-Miller, D.; Breen, E.C.; Muscatell, K.A.; Eisenberger, N.I.; Irwin, M.R. Inflammatory cytokines and nuclear factor-kappa B activation in adolescents with bipolar and major depressive disorders. *Psychiatry Res.* 2016, 241, 315–322. [CrossRef]

54. Bai, Y.M.; Su, T.P.; Li, C.T.; Tsai, S.J.; Chen, M.H.; Tu, P.C.; Chiou, W.F. Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. *Bipolar Disord.* 2015, 17, 269–277. [CrossRef]

55. Doganavsargil-Baysal, O.; Cinemre, B.; Aksoy, U.M.; Akbas, H.; Metin, O.; Fettahoglu, C.; Gokmen, Z.; Davran, F. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. *Hum. Psychopharmacol.* 2013, 28, 160–167. [CrossRef]

56. Hoseth, E.Z.; Ueland, T.; Dieset, I.; Birnbaum, R.; Shin, J.H.; Kleinman, J.E.; Hyde, T.M.; Morch, R.H.; Hope, S.; Lekva, T.; et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. *Schizophr. Bull.* 2017, 43, 881–890. [CrossRef]

57. Teixeira, A.L.; de Sousa, R.T.; Zanetti, M.V.; Brunoni, A.R.; Busatto, G.F.; Zarate, C.A., Jr.; Gattaz, W.F.; Machado-Vieira, R. Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. *Hum. Psychopharmacol.* 2015, 30, 52–56. [CrossRef]

58. Munkholm, K.; Vinberg, M. Cytokines in bipolar disorder: A systematic review and meta-analysis. *J. Affect. Disord.* 2013, 144, 16–27. [CrossRef]

59. Grassi-Oliveira, R.; Brietzke, E.; Pezzi, J.C.; Lopes, R.P.; Teixeira, A.L.; Bauer, M.E. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. *Psychiatry Clin. Neurosci.* 2009, 63, 202–208. [CrossRef]

60. Huang, M.H.; Chen, M.H.; Tu, P.C.; Bai, Y.M.; Su, T.P.; Yang, B.H.; Liu, R.S.; Li, C.T. Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression. *J. Affect. Disord.* 2018, 235, 250–256. [CrossRef] [PubMed]

61. Dellarole, A.; Morton, P.; Brambilla, R.; Walters, W.; Summers, S.; Bernardes, D.; Grilli, M.; Bethea, J.R. Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling. *Brain Behav. Immun.* 2014, 41, 65–81. [CrossRef] [PubMed]

62. Liguz-Lecznar, M.; Zakrzewska, R.; Kossut, M. Inhibition of Tnf-alpha R1 signaling can rescue functional cortical plasticity impaired in early post-stroke period. *Neurobiol. Aging* 2015, 36, 2877–2884. [CrossRef]
64. Becker, D.; Deller, T.; Vlachos, A. Tumor necrosis factor (TNF)-receptor 1 and 2 mediate homeostatic synaptic plasticity of denervated mouse dentate granule cells. Sci. Rep. 2015, 5, 12726. [CrossRef] [PubMed]

65. Stellwagen, D.; Malenka, R.C. Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440, 1054–1059. [CrossRef] [PubMed]

66. Rizzo, F.R.; Musella, A.; De Vito, F.; Fresegnia, D.; Bullitta, S.; Vanni, V.; Guadalupi, L.; Stamparoni Bassi, M.; Buttari, F.; Mandolesi, G.; et al. Tumor Necrosis Factor and Interleukin-1beta Modulate Synaptic Plasticity during Neuroinflammation. Neural Plast. 2018, 2018, 8430123. [CrossRef]

67. Luo, D.; Luo, Y.; He, Y.; Zhang, H.; Zhang, R.; Li, X.; Dobrucki, W.L.; Sinusas, A.J.; Sessa, W.C.; Min, W. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am. J. Pathol. 2006, 169, 1886–1898. [CrossRef]

68. Tartaglia, L.A.; Weber, R.F.; Figari, I.S.; Reynolds, C.; Palladino, M.A., Jr.; Goeddel, D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 1991, 88, 9292–9296. [CrossRef]

69. Wajant, H.; Siegmund, D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. Front. Cell Dev. Biol. 2019, 7, 91. [CrossRef]

70. Nanes, M.S. Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology. Gene 2003, 321, 1–15. [CrossRef]

71. MacEwan, D.J. TNF receptor subtype signalling: Differences and cellular consequences. Cell Signal. 2002, 14, 477–492. [CrossRef]

72. Russell, A.E.; Jun, S.; Sarkar, S.; Geldenhuys, W.J.; Lewis, S.E.; Rellick, S.L.; Simpkins, J.W. Extracellular vesicles secreted in response to cytokine exposure increase mitochondrial oxygen consumption in recipient cells. Front. Cell. Neurosci. 2019, 13, 51. [CrossRef] [PubMed]